KDU731
Modify Date: 2024-01-15 11:55:13
KDU731 structure
|
Common Name | KDU731 | ||
|---|---|---|---|---|
| CAS Number | 1610610-48-4 | Molecular Weight | 396.40 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H16N6O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of KDU731KDU731, an orally active C. parvum PI4K inhibitor with an IC50 value of 25 nM, blocks Cryptosporidium infection in vitro and in vivo[1][2]. KDU731 is a promising drug candidate for the treatment of diarrhea caused by Cryptosporidium and meets a broad range of safety[2]. |
| Name | KDU731 |
|---|
| Description | KDU731, an orally active C. parvum PI4K inhibitor with an IC50 value of 25 nM, blocks Cryptosporidium infection in vitro and in vivo[1][2]. KDU731 is a promising drug candidate for the treatment of diarrhea caused by Cryptosporidium and meets a broad range of safety[2]. |
|---|---|
| Related Catalog | |
| Target |
PI4K |
| In Vivo | KDU731 (orally administration; 7 or 10mg/kg; 16 days) has potent activity against Cryptosporidium in immunocompromised IFN-γ KO mice and dramatically reduces oocyst shedding[2]. KDU731 (orally administration; 5 mg/kg; every 12 hours for 7 days) is tolerated in all calves, and treated calves shed significantly fewer oocysts than vehicle treated calves in their stool[2]. Animal Model: 6-8 week old C57BL/6 IFN-γ-knockout mice with 10,000 oocysts[1] Dosage: 7 or 10 mg/kg Administration: Orally administration; 7 or 10 mg/kg; 16 days Result: Resulted in significant reduction of oocyst shedding. Animal Model: Neonatal calves with 5 x 107 oocysts[1] Dosage: 5 mg/kg Administration: Orally administration; 5 mg/kg; every 12 hours for 7 days Result: Resulted in significant reduction of oocyst shedding in treated calves in their stool. |
| References |
| Molecular Formula | C22H16N6O2 |
|---|---|
| Molecular Weight | 396.40 |